177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma

This study tests a targeted radiation therapy called Lutetium-177 DOTATATE in children with high-risk neuroblastoma (an aggressive childhood cancer) that has come back or didn't respond to initial treatment. The treatment works by delivering radiation directly to tumor cells that carry a specific receptor. **You may be eligible if...** - You are older than 18 months at the time of enrollment - You have high-risk neuroblastoma that has relapsed or did not respond to first-line therapy - Your tumor shows uptake of a specific imaging agent (68Ga-DOTATATE) on a PET scan - Your life expectancy is greater than 3 months - You are in reasonable functional health (Lansky or Karnofsky score above 50%) **You may NOT be eligible if...** - You have not recovered from side effects of previous treatments - Your blood counts or organ function have not recovered sufficiently - You have had treatment within the past 2 weeks without a proper washout period - Your imaging does not show adequate tumor uptake of the radiotracer Talk to your doctor to see if this trial is right for you.